Reetta Virtakoivu

814 total citations
19 papers, 578 citations indexed

About

Reetta Virtakoivu is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Reetta Virtakoivu has authored 19 papers receiving a total of 578 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Immunology and 5 papers in Molecular Biology. Recurrent topics in Reetta Virtakoivu's work include Immune cells in cancer (8 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Immunotherapy and Immune Responses (5 papers). Reetta Virtakoivu is often cited by papers focused on Immune cells in cancer (8 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Immunotherapy and Immune Responses (5 papers). Reetta Virtakoivu collaborates with scholars based in Finland, United Kingdom and Germany. Reetta Virtakoivu's co-authors include Johanna Ivaska, Maija Hollmén, Sirpa Jalkanen, Jenna H. Rannikko, Miro Viitala, Juha Rantala, Teijo Pellinen, Riina Kaukonen, Elina Mattila and Anja Mai and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Development.

In The Last Decade

Reetta Virtakoivu

18 papers receiving 574 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Reetta Virtakoivu Finland 11 282 214 165 150 74 19 578
Arnaud Descot Germany 9 289 1.0× 152 0.7× 74 0.4× 114 0.8× 90 1.2× 9 473
Dror Alishekevitz Israel 11 269 1.0× 270 1.3× 191 1.2× 95 0.6× 103 1.4× 16 556
Hyeongil Kwak United States 14 338 1.2× 105 0.5× 102 0.6× 145 1.0× 99 1.3× 16 546
Camille L. Duran United States 12 347 1.2× 169 0.8× 133 0.8× 124 0.8× 167 2.3× 23 646
Xiaoxia Xing China 8 187 0.7× 127 0.6× 90 0.5× 108 0.7× 96 1.3× 9 394
Hiroko Fujimoto Japan 12 379 1.3× 225 1.1× 78 0.5× 64 0.4× 103 1.4× 17 617
Stefano Marastoni Italy 9 302 1.1× 110 0.5× 88 0.5× 78 0.5× 113 1.5× 14 522
Rashid Gabbasov United States 10 286 1.0× 158 0.7× 91 0.6× 56 0.4× 60 0.8× 21 525
Sayali Joseph United States 4 243 0.9× 135 0.6× 72 0.4× 82 0.5× 69 0.9× 6 481
Yawen Ju United States 12 205 0.7× 237 1.1× 93 0.6× 48 0.3× 42 0.6× 21 510

Countries citing papers authored by Reetta Virtakoivu

Since Specialization
Citations

This map shows the geographic impact of Reetta Virtakoivu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reetta Virtakoivu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reetta Virtakoivu more than expected).

Fields of papers citing papers by Reetta Virtakoivu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Reetta Virtakoivu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reetta Virtakoivu. The network helps show where Reetta Virtakoivu may publish in the future.

Co-authorship network of co-authors of Reetta Virtakoivu

This figure shows the co-authorship network connecting the top 25 collaborators of Reetta Virtakoivu. A scholar is included among the top collaborators of Reetta Virtakoivu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Reetta Virtakoivu. Reetta Virtakoivu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Rannikko, Jenna H., Pia Boström, Reetta Virtakoivu, et al.. (2025). Macrophage sensitivity to bexmarilimab-induced reprogramming is shaped by the tumor microenvironment. Journal for ImmunoTherapy of Cancer. 13(5). e011292–e011292. 3 indexed citations
2.
Arner, Emily N., Dina Alzhanova, Jill M. Westcott, et al.. (2024). AXL-TBK1 driven AKT3 activation promotes metastasis. Science Signaling. 17(867). eado6057–eado6057. 3 indexed citations
3.
Björkman, Mari, Reetta Virtakoivu, Juho Jalkanen, et al.. (2023). Abstract 2269: Bexmarilimab induces B-cell activation and autoantibody production. Cancer Research. 83(7_Supplement). 2269–2269.
4.
Wolf, Stefan, Jenna H. Rannikko, Reetta Virtakoivu, et al.. (2022). A distinct M2 macrophage infiltrate and transcriptomic profile decisively influence adipocyte differentiation in lipedema. Frontiers in Immunology. 13. 1004609–1004609. 16 indexed citations
5.
Virtakoivu, Reetta, et al.. (2022). Clever-1 positive macrophages in breast cancer. Breast Cancer Research and Treatment. 195(3). 237–248. 7 indexed citations
6.
Virtakoivu, Reetta, Jenna H. Rannikko, Miro Viitala, et al.. (2021). Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial. Clinical Cancer Research. 27(15). 4205–4220. 41 indexed citations
7.
Takeda, Akira, et al.. (2021). Lymphatic Endothelial Cell Activation and Dendritic Cell Transmigration Is Modified by Genetic Deletion of Clever-1. Frontiers in Immunology. 12. 602122–602122. 21 indexed citations
8.
Rantala, Juha, Antti Arjonen, Heikki Hakkarainen, et al.. (2020). Ex Vivo Modelling of Therapy Efficacy for Rare Krukenberg Tumors – A Report of Two Cases. 1–8. 2 indexed citations
9.
Bono, Petri, Reetta Virtakoivu, Felix Vaura, et al.. (2020). Immune activation in first-in-human anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) phase I/II MATINS trial: Part I dose-escalation, safety, and efficacy results.. Journal of Clinical Oncology. 38(15_suppl). 3097–3097. 6 indexed citations
10.
Viitala, Miro, et al.. (2019). Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8+ T-cell Response against Immunosuppressive Tumors. Clinical Cancer Research. 25(11). 3289–3303. 82 indexed citations
11.
Takeda, Akira, Olga Halle, Marika Karikoski, et al.. (2019). Clever-1 contributes to lymphocyte entry into the spleen via the red pulp. Science Immunology. 4(33). 14 indexed citations
12.
Hollmén, Maija, Reetta Virtakoivu, Panu Jaakkola, et al.. (2019). Biomarkers of immune switch induced by a novel anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in MATINS trial patients with advanced solid tumours. Annals of Oncology. 30. xi1–xi1. 2 indexed citations
13.
Viitala, Miro, et al.. (2018). Abstract 4744: Disruption of Clever-1 in macrophages activates the innate immune response and mediates tumor rejection. Cancer Research. 78(13_Supplement). 4744–4744. 1 indexed citations
14.
Viitala, Miro, Marika Karikoski, Pia Rantakari, et al.. (2018). Enhanced Antibody Production in Clever-1/Stabilin-1–Deficient Mice. Frontiers in Immunology. 9. 2257–2257. 13 indexed citations
15.
Peuhu, Emilia, Reetta Virtakoivu, Anja Mai, Anni Wärri, & Johanna Ivaska. (2017). Epithelial vimentin plays a functional role in mammary gland development. Development. 144(22). 4103–4113. 46 indexed citations
16.
Virtakoivu, Reetta, Anja Mai, Elina Mattila, et al.. (2015). Vimentin–ERK Signaling Uncouples Slug Gene Regulatory Function. Cancer Research. 75(11). 2349–2362. 109 indexed citations
17.
Arjonen, Antti, Riina Kaukonen, Elina Mattila, et al.. (2014). Mutant p53–associated myosin-X upregulation promotes breast cancer invasion and metastasis. Journal of Clinical Investigation. 124(3). 1069–1082. 134 indexed citations
18.
Virtakoivu, Reetta, Teijo Pellinen, Juha Rantala, Merja Perälä, & Johanna Ivaska. (2012). Distinct roles of AKT isoforms in regulating β1-integrin activity, migration, and invasion in prostate cancer. Molecular Biology of the Cell. 23(17). 3357–3369. 67 indexed citations
19.
Virtakoivu, Reetta, et al.. (2012). 451 Distinct Roles of AKT Isoforms in Regulating Beta1-integrin Activity, Migration and Invasion in Prostate Cancer. European Journal of Cancer. 48. S108–S108. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arnaud Descot Breakdown of academic impact, for papers by Dror Alishekevitz Breakdown of academic impact, for papers by Hyeongil Kwak Breakdown of academic impact, for papers by Camille L. Duran Breakdown of academic impact, for papers by Xiaoxia Xing Breakdown of academic impact, for papers by Hiroko Fujimoto Breakdown of academic impact, for papers by Stefano Marastoni Breakdown of academic impact, for papers by Rashid Gabbasov Breakdown of academic impact, for papers by Sayali Joseph Breakdown of academic impact, for papers by Yawen Ju
Rankless by CCL
2026